Novartis AG

NVS
NYSE
Last Updated: 1/23/2022 5:54:19 PM
Price
87.03
Changes
-1.16
% Change
-1.32
Volume
2767771
52 Week
High
98.52
52 Week
Low
79.34
About Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Novartis AG Company Details
CEO:   Joseph Jimenez
Country:   CH
Industry:   Drug Manufacturers—General
Website:   https://www.novartis.com
Exchange:   New York Stock Exchange
IPO\Launch Date:   2001-09-05
Novartis AG Company Executive Details
  Ms. Marie-France Tschudin
  Pres of Novartis Pharmaceuticals
  Dr. James E. Bradner M.D.
  Pres of Novartis Institutes for Biomedical Research
  Mr. Richard Saynor
  Chief Executive Officer of Sandoz
  Ms. Susanne Schaffert Ph.D.
  Pres of Novartis Oncology
  Mr. Robert Weltevreden
  Head of Customer & Technology Solutions

Novartis AG Latest News

Novartis Hopes to Have Another COVID Therapy on the Way


Novartis and Molecular Partners reported positive results for COVID-19 candidate ensovibep.


Published on: 2022-01-23 02:28:00

Impact on Symbol / Company: NVS

View News

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success


Vera: Biotech With 3 Mid-Stage Programs With Potential For Success


Published on: 2022-01-19 01:28:57

Impact on Symbol / Company: NVS

View News

Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I


Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I


Published on: 2022-01-18 08:00:00

Impact on Symbol / Company: NVS

View News

3 Top Biotech Stocks to Buy Right Now


Each of these companies possesses solid fundamentals and trades at reasonable valuations.


Published on: 2022-01-15 07:50:00

Impact on Symbol / Company: NVS

View News

7 Best Long-Term Stocks to Buy and Hold for the Next Decade


These seven long-term stocks are among the best picks for truly long-term investors looking for companies to hold for the next decade. The post 7 Best Long-Term Stocks to Buy and Hold for the Next Decade appeared first on InvestorPlace.


Published on: 2022-01-13 14:34:59

Impact on Symbol / Company: NVS

View News

Novartis CEO: We're moving toward filing Covid drug from Molecular Partners with FDA


Novartis CEO Vas Narasimhan sits down with CNBC's Meg Tirrell and the 'Squawk on the Street' team to discuss the company's latest Covid-19 treatment, which it licensed from Molecular Partners.


Published on: 2022-01-12 10:45:09

Impact on Symbol / Company: NVS

View News

Molecular (MOLN), Novartis Post Positive Data From COVID-19 Drug


Molecular (MOLN) and Novartis announce encouraging data from a phase II study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19. Shares of Molecular Partners gain on the same.


Published on: 2022-01-11 13:05:11

Impact on Symbol / Company: NVS

View News

Molecular Partners Stock Surges as Novartis Plans to License Covid-19 Drug


Novartis says it will license antiviral Covid-19 treatment ensovibep from Molecular Partners following positive trial results.


Published on: 2022-01-10 08:09:00

Impact on Symbol / Company: NVS

View News

Novartis To In-License COVID-19 Treatment From Molecular Partners, After Encouraging Mid-Stage Data


After getting positive trial data, Novartis AG (NYSE: NVS) said it would in-license a new drug developing with Molecular Partners AG (NASDAQ: MOLN) to treat COVID-19. Novartis will pay CHF 150 million to in-license ensovibep from Molecular Partners.


Published on: 2022-01-10 05:46:47

Impact on Symbol / Company: NVS

View News

Novartis (NVS) Partners With Alnylam for Liver-Targeted Therapies


Novartis (NVS) partners with Alnylam (ALNY) to collaborate on the discovery and the development of siRNA-based targeted therapy to restore functional liver cells.


Published on: 2022-01-07 18:23:06

Impact on Symbol / Company: NVS

View News

Buy Signals Sound For 14 Top January Dividends On Earth


Kiplinger "insights for investors" online, first published 91 "Top Dividend Stocks From Around The World" 7/13/20. Two Kiplinger articles provided this 105 Best Dividend Stocks on Earth list compiled 7/1/21.


Published on: 2022-01-07 16:33:30

Impact on Symbol / Company: NVS

View News

Novartis says U.S. court upholds Gilenya patent


Novartis AG said on Tuesday a U.S. court of appeals upheld the validity of a dosage regimen patent for its multiple sclerosis treatment Gilenya, allowing a permanent injunction against Chinese generic drugmaker HEC Pharma to stay in place until the patent expires in 2027.


Published on: 2022-01-04 01:44:00

Impact on Symbol / Company: NVS

View News

Grow your Money

We helps you in understanding the science behind growing the money, which will help you diversify your funds as per your requirements and helps in achieving your retirement goals, children education, investment in property, business or any smart looking startup ventures

Services we Offer

We offer several services including expert recommendations & suggestions on buying ETF, Mutual Funds, Bonds, Debt securities, Equities, Property invesments and several others

Live Market Data

We provide you live market data for your analysis, review and looking out for quick buying opportunities to help you